If you’d invested in: Metro Bank and Hikma Pharmaceuticals

published 14 July 2017

If only...

Jordan's Hikma Pharmaceuticals (LSE: HIK) makes generic and branded drugs, which it sells primarily in the US, the Middle East and north Africa. Despite a rise in revenue and profits for 2016, its shares fell as part of a wider selloff in generic drugmakers and on news that the US regulator withheld approval for its generic version of asthma drug Advair. The shares are down by more than 40% in the last year.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Explore More

Ben studied modern languages at London University's Queen Mary College. After dabbling unhappily in local government finance for a while, he went to work for The Scotsman newspaper in Edinburgh. The launch of the paper's website, scotsman.com, in the early years of the dotcom craze, saw Ben move online to manage the Business and Motors channels before becoming deputy editor with responsibility for all aspects of online production for The Scotsman, Scotland on Sunday and the Edinburgh Evening News websites, along with the papers' Edinburgh Festivals website.

Ben joined MoneyWeek as website editor in 2008, just as the Great Financial Crisis was brewing. He has written extensively for the website and magazine, with a particular emphasis on alternative finance and fintech, including blockchain and bitcoin.

As an early adopter of bitcoin, Ben bought when the price was under $200, but went on to spend it all on foolish fripperies.